Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE SEMI-ANNUAL BUSINES RESULTS
December 1, 2003
-
ARCHIVE Teijin: Sales Up, but Operating Profits Hit by R&D Costs
December 1, 2003
-
ARCHIVE Hearings on Late-night, Early-morning Drug Sales Held
December 1, 2003
-
ARCHIVE Sawai: Favorable GE Market Drives Strong Growth in Sales, Profits
December 1, 2003
-
ARCHIVE OTC NEWS IN BRIEF
December 1, 2003
-
ARCHIVE Kuraya Sanseido: Sales, Net Profits Up Slightly
December 1, 2003
-
ARCHIVE PRESS SEMINAR
December 1, 2003
-
ARCHIVE Kissei: Sales Increase 1.3%, Profits Up 281.2%
December 1, 2003
-
ARCHIVE WORLD NEWS IN BRIEF
December 1, 2003
-
ARCHIVE Nippon Shinyaku: Sales Up Slightly, Profits Hit by Higher Costs
December 1, 2003
-
COLUMN Maurer's Healthcare Insight (48)
December 1, 2003
-
ARCHIVE Kaken: Ordinary Profits Down, but R&D Tax Credit Boosts Net Profits
December 1, 2003
-
ARCHIVE Rewards for Innovativeness in New Drugs to Be Needed: Mr Ager of EFPIA
December 1, 2003
-
ARCHIVE Meiji Seika: Drug Division Sales Up 6.5% to \49.5 Bil.
December 1, 2003
-
ARCHIVE ICH-6 in Osaka Focuses on New Horizons and Future Challenges (1)
December 1, 2003
-
ARCHIVE Suzuken: Consolidated Sales Up 15% to \558.1 Bil.
December 1, 2003
-
ARCHIVE Chuikyo Discusses NPA Recommendation, Consumer Prices
December 1, 2003
-
ARCHIVE Toho: Sales Up 17.4%, Net Profits Up 44.9%
December 1, 2003
-
ARCHIVE REGULATORY NEWS IN BRIEF
December 1, 2003
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
December 1, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…